Vistagen Therapeutics Inc (VTGN)

Nov 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World

Nov 17, 2024

Nov 15, 2024

Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online

Nov 14, 2024

Nov 14, 2024

Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan

Nov 14, 2024

Nov 11, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

Nov 11, 2024

Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat

Nov 11, 2024

Nov 08, 2024

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - MSN

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks

Nov 08, 2024

Nov 07, 2024

Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com

Nov 07, 2024

Nov 07, 2024

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire

Nov 07, 2024

Nov 07, 2024

Vistagen reports Q2 EPS (42c), consensus (39c) - TipRanks

Nov 07, 2024

Nov 06, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com

Nov 06, 2024

Nov 05, 2024

Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire

Nov 05, 2024

Nov 05, 2024

Vistagen to Present Breakthrough SAD Treatment Data at 2024 NEI Congress | VTGN Stock News - StockTitan

Nov 05, 2024

Nov 02, 2024

Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 02, 2024

Nov 01, 2024

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise

Nov 01, 2024

Oct 31, 2024

VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com

Oct 31, 2024

Oct 21, 2024

Generalized Anxiety Disorder Pipeline 2024: Clinical Trials - openPR

Oct 21, 2024

Oct 15, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha

Oct 15, 2024

Oct 12, 2024

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN

Oct 12, 2024

Oct 11, 2024

Mental Disorder Treatment Market Global Industry Forecast - openPR

Oct 11, 2024

Oct 10, 2024

Vistagen, The Goldie Hawn Foundation, and MindUP students Rings the Nasdaq Stock Market Closing Bell on World Mental Health Day - Nasdaq

Oct 10, 2024

Oct 09, 2024

Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance UK

Oct 09, 2024

Oct 09, 2024

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - sharewise

Oct 09, 2024

Sep 24, 2024

Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Sep 24, 2024

Sep 24, 2024

Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance

Sep 24, 2024

Sep 24, 2024

Vistagen advances phase 3 trial for social anxiety treatment By Investing.com - Investing.com Australia

Sep 24, 2024

Sep 23, 2024

Vistagen advances phase 3 trial for social anxiety treatment - Investing.com

Sep 23, 2024

Sep 23, 2024

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - StockTitan

Sep 23, 2024

Sep 06, 2024

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga

Sep 06, 2024

Sep 06, 2024

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance

Sep 06, 2024

Sep 06, 2024

Mental Disorder Treatment Market Expected to Expand at a Steady - openPR

Sep 06, 2024

Sep 05, 2024

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance

Sep 05, 2024

Sep 03, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat

Sep 03, 2024

Sep 03, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World

Sep 03, 2024

Aug 30, 2024

Mental Disorder Treatment Market Detailed In New Research - openPR

Aug 30, 2024

Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada

Aug 28, 2024

Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay - Investing.com

Aug 28, 2024

Aug 24, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49 - Defense World

Aug 24, 2024

Aug 24, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50 Day Moving Average of $3.49 - MarketBeat

Aug 24, 2024

Aug 21, 2024

The Globe and Mail - The Globe and Mail

Aug 21, 2024

Aug 21, 2024

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - MSN

Aug 21, 2024

Aug 19, 2024

VTGN (Vistagen Therapeutics) 3-Year Revenue Growth Rate : -47.50% (As of Jun. 2024) - GuruFocus.com

Aug 19, 2024